cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

[1]  Wei-wei Wang,et al.  IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations , 2019, Brain pathology.

[2]  G. Reifenberger,et al.  FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas , 2019, Acta Neuropathologica.

[3]  E. Holland,et al.  Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. , 2019, Journal of neuropathology and experimental neurology.

[4]  M. Snuderl,et al.  Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas , 2019, Acta Neuropathologica Communications.

[5]  F. Ducray,et al.  CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.

[6]  H. Noushmehr,et al.  Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks , 2019, Neuro-oncology advances.

[7]  R. McLendon,et al.  MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. , 2019, Cancer research.

[8]  E. Holland,et al.  Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. , 2019, Neuro-oncology.

[9]  M. Kool,et al.  Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.

[10]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[11]  M. Snuderl,et al.  Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas , 2018, Journal of neuropathology and experimental neurology.

[12]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[13]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[14]  G. Reifenberger,et al.  cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification , 2017, Brain pathology.

[15]  David T. W. Jones,et al.  Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery , 2017, Acta neuropathologica communications.

[16]  Promita Bose,et al.  Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. , 2016, Cancer cell.

[17]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[18]  M. Papotti,et al.  Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas , 2016, Oncotarget.

[19]  S. McGuire.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[20]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[21]  G. Reifenberger,et al.  Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy , 2016, Acta Neuropathologica.

[22]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[23]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[24]  DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status , 2015, Acta neuropathologica communications.

[25]  Pieter Wesseling,et al.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.

[26]  Arie Perry,et al.  CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas , 2015, Journal of neuropathology and experimental neurology.

[27]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[28]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[29]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[30]  D. Brat,et al.  PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.

[31]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[32]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.

[33]  S. Coons,et al.  Mitosis identification in diffuse gliomas , 1998, Cancer.

[34]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.